Follow The Filings

ABOS Acumen Pharmaceuticals

Acumen Pharmaceuticals earnings company data as of 4:47 AM ET 10/21

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 11 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by ABOS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ABOS insider trades
  • None no insider bought on the open market
  • $90K sold by 2 insiders outside a trading plan
  • $205K sold by 1 insider under 10b5-1 plans
  1. Derrell Porter Director
    Sale
    $75K 32,300 shares at $2.33 48% of stake
    Traded Jun 15–17 Filed Jun 17
    ↗
  2. Nathan B Fountain Director
    Sale
    $14K 6,400 shares at $2.23 12% of stake
    Traded Jun 9 Filed Jun 10
    ↗
  3. Derek M Meisner Chief Legal Officer & Corp Sec
    Planned sale
    $6,813 2,090 shares at $3.26 1.2% of stake
    Traded Mar 6 Filed Mar 10
    ↗
  4. Derek M Meisner Chief Legal Officer & Corp Sec
    Planned sale
    $28K 9,406 shares at $3.01 5.1% of stake
    Traded Feb 27 Filed Mar 3
    ↗
  5. Derek M Meisner Chief Legal Officer & Corp Sec
    Planned sale
    $53K 17,756 shares at $3.00 9.3% of stake
    Traded Jan 26–28 Filed Jan 28
    ↗
  6. Derek M Meisner Chief Legal Officer & Corp Sec
    Planned sale
    $11K 5,633 shares at $1.90 3.1% of stake
    Traded Jan 23 Filed Jan 23
    ↗
  7. Derek M Meisner Chief Legal Officer & Corp Sec
    Planned sale
    $79K 43,840 shares at $1.80 34% of stake
    Traded Jan 8–12 Filed Jan 12
    ↗
  8. Derek M Meisner Chief Legal Officer & Corp Sec
    Planned sale
    $28K 13,871 shares at $1.98 9.4% of stake
    Traded Jan 6–7 Filed Jan 7
    ↗

Also filed in the last 12 months, not counted as buying or selling: 34 sales to cover taxes, 16 stock grants, and 6 option exercises.

SEC filings

Recent issuer filings from EDGAR, 15 shown.

Filed Form Detail Links
8-K 7.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G — Filing Doc
424B3 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,3.02,7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.